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Virus-like particles (VLPs) are emerging nanoscale protein assemblies applied as
prophylactic vaccines and in development as therapeutic vaccines or cargo delivery
systems. Downstream processing (DSP) of VLPs comes both with challenges and
opportunities, depending on the complexity and size of the structures. Filtration,
precipitation/re-dissolution and size-exclusion chromatography (SEC) are potent
technologies exploiting the size difference between product and impurities. In this
study, we therefore investigated the integration of these technologies within a single
unit operation, resulting in three different processes, one of which integrates all three
technologies. VLPs, contained in clarified lysate from Escherichia coli, were precipitated
by ammonium sulfate, washed, and re-dissolved in a commercial cross-flow filtration
(CFF) unit. Processes were analyzed for yield, purity, as well as productivity and were
found to be largely superior to a reference centrifugation process. Productivity was
increased 2.6-fold by transfer of the wash and re-dissolution process to the CFF
unit. Installation of a multimodal SEC column in the permeate line increased purity to
96% while maintaining a high productivity and high yield of 86%. In addition to these
advantages, CFF-based capture and purification allows for scalable and disposable
DSP. In summary, the developed set-up resulted in high yields and purities, bearing
the potential to be applied as an integrated process step for capture and purification of
in vivo-assembled VLPs and other protein nanoparticles.
Keywords: virus-like particles, precipitation, cross-flow filtration, integrated processing, downstream processing
Abbreviations: (NH4)2SO4, ammonium sulfate; CFF, cross-flow filtration; DAD, diode array detector; DF, diafiltration;
DSP, downstream processing; DTT, dithiothreitol; E. coli, Escherichia coli; HBcAg, hepatitis B virus core antigen; HCP,
host cell protein; HT-CGE, high-throughput capillary gel electrophoresis; mAb, monoclonal antibody; MALS, multi-angle
light scattering; mmSEC, multimodal size-exclusion chromatography; P&ID, piping and instrumentation diagram; PEG,
polyethylene glycol; QELS, quasi-elastic light scattering; RT, room temperature; SEC, size-exclusion chromatography; TEM,
transmission electron microscopy; TMP transmembrane pressure; UF, ultrafiltration; UV, ultraviolet; UV/Vis, ultraviolet and
visible light; VLP, virus-like particle.
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INTRODUCTION
Vaccination has reduced morbidity and mortality world-
wide, especially since the introduction of the World Health
Organization’s Expanded Program on Immunization
(Greenwood, 2014). Expansion of the vaccine portfolio by
virus-like particles (VLP) has opened up new opportunities,
such as the prevention or treatment of cancer (Ding et al.,
2009; Klamp et al., 2011; Goldinger et al., 2012; Bryan et al.,
2016; Lizotte et al., 2016; Bolli et al., 2018; Palladini et al., 2018;
Mohsen et al., 2019a,b). However, especially VLP downstream
processing (DSP) faces major challenges, such as low yields and
the lack of platform processes or rapid analytical techniques.
This is due to the complexity of the product and the associated
processes, resulting in high development and production costs
(Ladd Effio and Hubbuch, 2015). The structural properties of
VLPs are similar or identical to the corresponding virus structure
they are derived from Zeltins (2013). Composed of at least
one type of viral structural protein, they are in a size range of
approximately 25 to 200 nm (Chung et al., 2010; Reiter et al.,
2019). Incorporation of foreign epitopes into VLP-forming viral
structural proteins results in so-called chimeric VLPs (Pumpens
and Grens, 2001). In a previous study, we observed that upon
insertion of smaller peptides, the size of chimeric Hepatitis B
core antigen (HBcAg) VLPs remained comparable to native
HBcAg VLPs with a diameter of 31± 2 to 33± 3 nm (Selzer and
Zlotnick, 2017; Rüdt et al., 2019). During production, the size
difference between VLPs and host cell proteins (HCPs) as well
as other smaller contaminants can be exploited for DSP of VLPs
(Ladd Effio and Hubbuch, 2015).
A typical VLP production process is shown in Figure 1
including unit operations such as centrifugation, filtration,
and chromatography. Bind and elute chromatography, the
work horse in biopharmaceutical manufacturing for capture,
purification, and polishing, suffers from low dynamic binding
capacities (Ladd Effio and Hubbuch, 2015), diffusion limitations
(Kramberger et al., 2015), and often too small pore sizes (Kattur
Venkatachalam et al., 2014) for the purification of VLPs. Size
differences between VLPs and the bulk of host cell contaminants
can be exploited by size-sensitive techniques such as size-
exclusion chromatography (SEC) – especially for analytical
purposes (Ladd Effio et al., 2016) – precipitation, filtration,
and ultracentrifugation (Ladd Effio and Hubbuch, 2015). While
ultracentrifugation is applied to lab-scale processes (Jiang et al.,
1992; Mason et al., 1996; Ausar et al., 2006), scalability and
variability issues, among others, hamper its application to
industrial-scale processes (Koho et al., 2012; Kleiner et al., 2015).
Originally developed for the fractionation of blood by Edward
Cohn and coworkers in the 1940s (Cohn, 1941; Cohn et al.,
1946), precipitation of contaminants or native precipitation of
the product are promising alternatives for protein separation
and purification (Martinez et al., 2019). In this context, native
precipitation has been reported as highly selective for VLPs
(Tsoka et al., 2000; Kim et al., 2010; Koho et al., 2012; Zahin
et al., 2016), since larger proteins or protein assemblies are
more susceptible to precipitation (Rothstein, 1993). The steric
exclusion effect associated with the frequently applied precipitant
polyethylene glycol (PEG) generally leads to steeper slopes in
the precipitation curves for larger proteins (Iverius and Laurent,
1967; Sim et al., 2012). For precipitation with kosmotropic
salts, surface charge is, however, thought to have a greater
effect than size (Curtis et al., 1998). Separation of product-
containing precipitate and supernatant can be achieved by
centrifugation or filtration. While PEG has been successfully
applied to VLP precipitation (Tsoka et al., 2000; Koho et al.,
2012), its application is limited when filtration is used as solid-
liquid separation technique, as filtration performance is impaired
by a PEG-induced viscosity increase (Plisko et al., 2016; Li and
Zydney, 2017). Next to PEG of various molecular weights, the
kosmotropic salt ammonium sulfate [(NH4)2SO4] is a commonly
applied precipitant (Kim et al., 2010; Zahin et al., 2016; Kazaks
et al., 2017). In a study on adenovirus (Schagen et al., 2000), dead-
end filtration has been applied to retain (NH4)2SO4-precipitated
virus but exhibited only 46-61% recovery from the filter. As an
alternative to dead-end filtration, cross-flow filtration (CFF) in
diafiltration (DF) mode has been applied to recover precipitated
monoclonal antibodies (mAbs) (Venkiteshwaran et al., 2008;
Kuczewski et al., 2011; Hammerschmidt et al., 2016). Precipitate
was retained by a microfilter, allowing for a wash in DF mode. In
CFF, turbulent flow along the membrane surface ensures better
recovery from the filter (Davies and Smith, 2010), also reducing
concentration polarization and fouling (van Reis and Zydney,
2007). A main advantage of precipitate recovery by CFF over
centrifugation lies in avoiding the compaction of precipitate that
occurs during centrifugation, which allows for shorter precipitate
re-dissolution times using CFF (Hammerschmidt et al., 2016).
Additionally, in the above-mentioned studies, precipitation and
wash were conducted as integrated CFF-based process steps that
showed a higher wash efficiency as compared to centrifugation
(Kuczewski et al., 2011; Hammerschmidt et al., 2016). In these
studies, the precipitate was re-dissolved by dilution.
This said, it seems promising to dissolve precipitated product
by DF into a re-dissolution buffer. Product could subsequently
be recovered in the permeate stream as it passes the microfilter.
Implementing this approach, the permeate can be separated
into fractions allowing for purity increase and concentration
adjustment by strategic pooling while undissolved contaminants
are retained by the microfilter.
In our experience with DSP of Escherichia coli (E. coli)-derived
VLPs, HCP reduction poses a minor challenge as compared to
nucleic acid depletion, demanding for a purification method to
reduce the nucleic acid burden. One commonly applied strategy
is the supplementation of lysate with Benzonase, a nucleic acid
digestion enzyme. In recent years, a novel multimodal SEC
(mmSEC) medium Capto Core 400/700 has been developed
that found successful application in the purification of VLPs,
decreasing impurity levels significantly (Zhao et al., 2015;
Lagoutte et al., 2016; Somasundaram et al., 2016). Integration
of a precipitation, wash, and re-dissolution step on a CFF
system together with this novel mmSEC medium seems
therefore promising.
In the light of the above, the objective of our study was
to develop an integrated membrane-aided precipitation, wash,
and re-dissolution process for capture and purification of VLPs.
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FIGURE 1 | Typical production process for intracellularly produced, in vivo-assembled virus-like particles (VLPs). Virus structural proteins can be expressed in a
variety of host systems, such as E. coli, yeast or plant cells (Ladd Effio and Hubbuch, 2015). After harvest and lysis, cell debris are removed by solid-liquid separation
and the VLPs remain in solution. VLPs are then captured and purified, followed by an optional dis- and reassembly step, which has shown to increase VLP stability,
homogeneity and immunogenicity (Mach et al., 2006; Klamp et al., 2011; Zhao et al., 2012). Finally, the product is polished and formulated. The process steps that
were investigated as integrated unit operations in this study are highlighted in blue.
The set-up was realized on a commercial CFF unit coupled
to a basic preparative chromatography system for monitoring
of ultraviolet (UV) absorbance at 280 nm and fractionation.
Three process variants were developed, the simplest of which
comprised precipitation, wash, and re-dissolution within an
integrated CFF-based set-up (Figure 2, Process Basic). To
improve product purity, this method was further either extended
by installation of a Capto Core 400 column in the CFF permeate
line (Process mmSEC) or by pretreatment of the lysate with
Benzonase prior to the precipitation step (Process Nuclease). As
a model VLP, a C-terminally truncated chimeric HBcAg VLP
was investigated. The three process variants were compared
to a centrifugation-based precipitation, wash and re-dissolution
process (Process Reference).
MATERIALS AND METHODS
Materials, Buffers, and VLPs
All chemicals were purchased from Merck Millipore (Darmstadt,
Germany), unless otherwise stated. Solutions and buffers
were prepared with ultrapure water (PURELAB Ultra, ELGA
LabWater, Lane End, United Kingdom). A buffer consisting of
50 mM Tris, 100 mM NaCl, 1 mM EDTA (AppliChem GmbH,
Darmstadt, Germany), pH 8 was used as lysis buffer. The wash
buffer was created from lysis buffer that was adjusted to 0.25%
(v/v) polysorbate 20 (AppliChem GmbH, Darmstadt, Germany)
with a 10% (v/v) polysorbate 20 stock solution and to 150 mM
(NH4)2SO4 (AppliChem GmbH, Darmstadt, Germany) with a
1 M (NH4)2SO4 stock solution. In the Nuclease process and
respective experiments, the digestion and nuclease wash buffers
were both 50 mM Tris at pH 8, containing 20 mM NaCl,
0.2 mM EDTA, and 2 mM MgCl2. The re-dissolution buffer
was 50 mM Tris at pH 8 for all experiments. All buffers were
pH-adjusted with 32% HCl. BioNTech Protein Therapeutics
generously provided the chimeric HBcAg VLP plasmid. HBcAg
was expressed in E. coli and liberated by lysis as described
in Supplementary Information S1. Its extinction coefficient at
280 nm of 1.558 L g−1 cm−1 was derived from the web-tool
ProtParam (Gasteiger et al., 2005) and used for all methods. E. coli
lysate was diluted to ensure a consistent HBcAg content, resulting
in HBcAg concentrations between 2.60 and 2.66 g/L, used as
lysate for all processes and experiments.
Precipitation and Re-dissolution
Screening
For processes Reference, Basic, mmSEC, and Nuclease,
optimal parameters for the precipitation were determined
in screening experiments. Screening experiments for precipitant
concentration were performed at a small scale in reaction tubes.
Lysate was used either untreated or pretreated. Pretreatment
comprised overnight dialysis with Slide-A-Lyzer G2 cassettes
(10 kDa, 3 mL, Thermo Scientific, Rockford, IL, United States)
into the digestion buffer with or without addition of >114 U/mL
of Benzonase (Sigma Aldrich, Saint Louis, MO, United States)
to the lysate. In 1.5 mL reaction tubes, 170 or 200 µL of
these solutions, adjusted to 0.25% (v/v) polysorbate 20, were
mixed with different volumes of (NH4)2SO4 stock solution and
incubated for 30 min at room temperature (RT), which was
between 22 and 23◦C for all experiments. The solution was spun
down at 17000 rcf for 2 min in a tabletop centrifuge Heraeus
Pico 17 (Thermo Electron LED GmbH, Osterode am Harz,
Germany) and the supernatant was recovered. For screening of
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FIGURE 2 | Schematic overview of the processes investigated in this study. The Reference process is shown at the top, consisting of centrifugation-based
precipitation, wash, and re-dissolution. Process transfer to a cross-flow filtration (CFF) unit resulted in the Basic process. Transferred process steps are wash and
re-dissolution, highlighted in blue and green, respectively. Wash and re-dissolution are multiple process steps consisting of repeated centrifugation (highlighted in
yellow) in the Reference process. In the Basic process, these are reduced to two consecutive diafiltration (DF) steps by simply switching between diafiltration buffers
(Figure 3). Alternative CFF process variants, either Nuclease or mmSEC, are modifications from the Basic process. The Nuclease process adds a nucleic acid
digestion and a 300 kDa wash step preceding precipitation and continues like the Basic process. The mmSEC process sequence is identical to the Basic process
sequence but has a modified re-dissolution step (DF II) including a multimodal size-exclusion chromatography (mmSEC) column in the permeate line. (NH4)2SO4,
ammonium sulfate; HCP, host cell protein; UF/DF, ultrafiltration/diafiltration; VLP, virus-like particle.
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the incubation time during precipitation, untreated lysate was
precipitated in a 20 mL batch, sampled at 10 min intervals, and
treated as described above.
Small-scale re-dissolution experiments were conducted to
test the influence of solution components on re-dissolution
efficiency. Pooled fractions F3-F11 of the mmSEC process
were concentrated to 7.74 g/L using 20 mL VivaSpins with
100 kDa MWCO (Sartorius Stedim Biotech GmbH, Göttingen,
Germany). In 1.5 mL tubes, 0.5 mL of concentrated HBcAg
solution was mixed with 0.5 mL of five different solutions.
Solutions were (a) 200 mM NaCl, 50 mM Tris, 2 mM EDTA,
pH 8.0, (b) 40 mM NaCl, 50 mM Tris, 2 mM EDTA, pH
8.0, (c) 200 mM NaCl, 50 mM Tris, 0.4 mM EDTA, 4 mM
MgCl2, pH 8.0, (d) supernatant of the precipitation step during
the Reference (section “Centrifugation-Based Wash and Re-
dissolution”) process, and (e) supernatant of the wash step during
the Reference process. Solutions were adjusted to 0.25% (v/v)
polysorbate 20 and then to 150 mM (NH4)2SO4 for precipitation.
Samples were incubated for 30 min at 300 rpm and 23◦C in
a thermo-shaker Thermomixer comfort (Eppendorf, Hamburg,
Germany) and subsequently centrifuged at 15294 rcf in an
Eppendorf 5810R centrifuge for 20 min at 20◦C. Supernatant was
removed by pipetting. A volume of 1 mL re-dissolution buffer
was added and the pellet was resuspended. The reaction tubes
were incubated at 10 rpm at RT in an overhead shaker LD-
79 (Labinco, Breda, Netherlands) for 60 min, centrifuged with
identical settings, and the supernatant was recovered.
CFF Instrumentation and Set-Up
The CFF precipitation, wash, and re-dissolution set-up (Figure 3)
was based on a KrosFlo Research KRIIi CFF system with
an automatic backpressure valve (Spectrum Labs, Rancho-
Dominguez, CA, United States), a stirred cell (Sartorius Stedim
Biotech GmbH, Göttingen, Germany) as reservoir, and 0.2 µm
200 cm2 Hydrosart or 300 kDa MWCO 200 cm2 polyether
sulfone (PESU) membranes (both Sartocon Slice 200) with
corresponding membrane holders (all Sartorius Stedim Biotech
GmbH, Göttingen, Germany). The three stirred cell inlet ports
were connected to retentate, wash buffer, and re-dissolution
buffer lines. A Sensirion Liquid Flow Meter SLS-1500 (Sensirion
AG, Stäfa, Switzerland) was installed at the permeate outlet of the
membrane holder and connected with a 1/16” PEEK capillary
with 0.75 mm inner diameter to the wash valve of an ÄKTA
Start (GE Healthcare, Uppsala, Sweden). On-line ÄKTA Start
UV sensor data were converted to on-line concentration data
applying Beer’s law using the HBcAg extinction coefficient. The
permeate was fractionated in either 15 mL (wash) or 5 mL
(re-dissolution) fractions in 15 mL tubes (Corning, Reynosa,
TAM, Mexico). In all presented filtration processes, a constant
permeate flow rate of 2 mL/min was set and maintained using
the automatic backpressure valve either by manual valve control
(Process Basic) or automatic control (Processes mmSEC and
Nuclease). Therefore, the backpressure valve controller was fed
with flow rate data of the flow meter (at >1 Hz) instead of
transmembrane pressure data as in normal operation mode
using a custom-written communication MATLAB 2018b script
(The Mathworks, Natick, MA, United States). Flow rate, path,
and control were optimized in pre-experiments, and data were
temporally aligned considering delay volumes (for more detail see
Supplementary Information S2).
Precipitation, Wash, and Re-dissolution
Process by CFF
Diluted lysate, adjusted to 0.25% (v/v) polysorbate 20, was filled
into the aforementioned stirred cell with three inlets and two
outlets. One outlet was capped with an injection plug (Fresenius
Kabi, Bad Homburg, Germany) for sampling, the other outlet
either closed or connected to the suction port of the CFF
feed pump. A Minipuls 3 peristaltic pump (Gilson, Villiers le
Bel, France) was used to pump 1 M (NH4)2SO4 solution at
1 mL/min through one of the inlet ports of the cell up to a final
concentration of 150 mM (NH4)2SO4 (Figure 3). The flow rate
was monitored using a Sensirion Liquid Flow Meter SLS-1500.
The stirred cell was set to minimal stirring speed. The solution
was incubated for 30 min at RT. During incubation, 250 µL
samples were taken every 10 min.
Three wash and re-dissolution process variants were
examined, referred to as Basic, mmSEC, and Nuclease (Figure 2).
The Basic process consisted of wash and re-dissolution of
precipitate suspension by constant volume DF against wash
and re-dissolution buffer, respectively, and fractionation of
the permeate. CFF feed flow rate in all filtration steps was
30 mL/min. Compared to the Basic process, the mmSEC process
included a Capto Core 400 HiScreen column (GE Healthcare,
Uppsala, Sweden) with a nominal column volume of 4.7 mL in
the permeate line downstream of the fractionation valve of the
ÄKTA Start (Figure 3). The Nuclease process was conducted
like the Basic process with additional pretreatment of the
lysate prior to precipitation. The lysate was diluted 1:5 with a
buffer containing 50 mM Tris and 2.5 mM MgCl2 at pH 8 to
optimize the conditions for the digestion of nucleic acids by
Benzonase, resulting in the composition of the digestion buffer.
Benzonase was added to a concentration of ≥114 Units/mL and
incubated overnight for 16 h at 80 rpm and 23◦C in a 225 mL
tube in a MaxQ 6000 Shaker (Thermo Scientific, Marietta,
OH, United States). The solution was concentrated five-fold by
ultrafiltration (UF) in the CFF unit with the 300 kDa membrane.
The solution was diafiltered for five diafiltration volumes
using nuclease wash buffer. The permeate of UF and DF was
fractionated into 15 mL fractions. The retentate was processed
analogous to the lysate in the other processes.
Centrifugation-Based Wash and
Re-dissolution
In a centrifugation-based process (Figure 2, process Reference),
precipitation was performed identically to the experimental
procedure for the CFF runs, whereas wash and re-dissolution
were performed as a centrifugation protocol. The suspension
of 20 mL was centrifuged at 17387 rcf at 20◦C for 20 min.
Supernatant was removed and the pellet was resuspended.
The procedure including centrifugation and resuspension
was repeated with re-dissolution buffer. The suspension was
transferred into a stirred cell and stirred at minimal speed. After
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FIGURE 3 | Piping and instrumentation diagram (P&ID) of the precipitation and cross-flow filtration (CFF) setup. The set-up used for wash and re-dissolution of the
CFF processes Basic and Nuclease is shown. For process Nuclease, the depicted set-up was used with different membranes (300 kDa and 0.2 µm) for the
respective wash steps. The mmSEC process included an additional multimodal size-exclusion chromatography column (mmSEC) in the permeate stream,
highlighted in blue. The precipitation set-up consists of the components highlighted in gray on the left and the stirred reservoir. Precipitant was ammonium sulfate
[(NH4)2SO4]. Gray highlighted components were removed after completion of precipitation. C, control; F, flow rate; I, indicate; P, pressure; R, record; U, multivariable;
UV, ultraviolet.
1, 2, and 3 h, a sample was taken, spun down at 17000 rcf for 2 min
in the tabletop centrifuge, and the supernatant was recovered.
Analytical Characterization
Size-exclusion chromatography (SEC) was coupled with a diode
array detector (DAD), multi-angle light scattering (MALS), and
quasi-elastic light scattering (QELS) to quantify and specify
differently sized species. An Agilent BioSEC-5 4.6 × 300 mm,
5 µm, 1000 Å column (Agilent, Santa Clara, CA, United States)
was used at a Dionex Ultimate 3000 RS UHPLC system
controlled by Chromeleon version 6.8 SR15 (Thermo Fisher
Scientific, Waltham, MA, United States). The method was
isocratic for 14 min at a flow rate of 0.4 mL/min with 50 mM
potassium phosphate buffer at pH 7.4. The injection volume
was 20 µL. The outlet of the DAD was connected to a Dawn
Heleos 8+ MALS/QELS system (Wyatt Technology Corporation,
Santa Barbara, CA, United States). MALS and QELS data were
analyzed with the ASTRA V software (Version 5.3.4.15, Wyatt
Technology Corporation, Santa Barbara, CA, United States) and
resulted in root mean square radius (rms) and molecular weight
(both assessed by MALS) and hydrodynamic radius (assessed
by QELS). For protein separation and quantitation, a Caliper
LabChip GX II (PerkinElmer, Waltham, MA, United States)
high-throughput capillary gel electrophoresis (HT-CGE) device
was employed. An HT Protein Express LabChip and the
corresponding HT Protein Express Reagent Kit were used
and results analyzed with LabChip GX software (Version
4.2.1745.0, PerkinElmer, Waltham, MA, United States). Analyses
were performed using the HT Protein Express 200 assay
in reduced mode using dithiothreitol (DTT, Amresco, Solon,
OH, United States) according to the assay standard operation
procedure provided by the manufacturer. For data analysis, all
peaks of 21.5± 1 kDa were regarded as HBcAg monomers, which
is the form in which HBcAg is present after sample preparation.
The range derived from experiments with pure HBcAg. For SDS
PAGE, LDS sample buffer, MES running buffer, and NuPage 4–
12% BisTris Protein Gels were used and run on a PowerEase 500
Power Supply (all Invitrogen, Carlsbad, CA, United States) in
reduced mode with 50 mM DTT in the sample solution according
to the manufacturer’s manual with minor adaptations. The gel
was stained with a Coomassie blue solution. CFF re-dissolution
samples of fractions with maximum concentration were analyzed
by transmission electron microscopy (TEM) on a Fecnei Titan3
80–300 microscope (FEI company, Hillsboro, OR, United States).
Samples were adjusted to 0.5–1 g/L with ultrapure water and
filtered with a 0.2 µm syringe filter. Sample preparation and
image analysis were conducted similarly to previous studies with
chimeric HBcAg VLPs (Rüdt et al., 2019). Hydrophilization and
staining solutions were 1% (w/v) alcian blue 8GX (Alfa Aesar,
Ward Hill, MA, United States) in 1% acetic acid solution and
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2% ammonium molybdate(VI) (Acros Organics, Geel, Belgium)
solution (pH 6.25, adjusted with NaOH), respectively.
Calculation of Yield, Purity, and
Productivity Measures
The yield Y of a process was calculated by
Y =
∑end
i=start mFi
mlysate
, (1)
where mlysate is the mass of HBcAg, calculated from the processed
lysate volume and HBcAg concentration as determined by HT-
CGE, and mFi is the mass of HBcAg in re-dissolution fraction
F as determined by SEC, where fractions were considered from
fraction Fstart to Fend. HT-CGE purity was determined by the
ratio of HBcAg concentration to total protein concentration
in HT-CGE samples. SEC purity was calculated by the ratio
of HBcAg peaks to total peak area at 280 nm (for details on
peak identification, the reader is referred to Supplementary
Information S3). A260/A280 was calculated by dividing the
cumulated peak areas at 260 nm by the cumulated peak areas at
280 nm. Absolute spatial productivity P was calculated by
P = mHBcAg,recoveredtprocess , (2)
where mHBcAg,recovered is the accumulated mass of pooled
fractions and tprocess the time to complete the process starting
with precipitated material through to recovery of the product.
Relative spatial productivity was derived by the ratio of
absolute productivities to the absolute productivity of the
Reference process.
RESULTS
Precipitation
In pre-experiments, 150 mM (NH4)2SO4 was determined as
optimal concentration for all process variants, where most of
the product is found in the precipitate. Figure 4 shows HT-
CGE and SDS PAGE data of the clarified supernatant of small-
scale precipitation experiments from (I) lysate, (II) lysate with
added Benzonase dialyzed against digestion buffer overnight, and
(III) lysate dialyzed against digestion buffer over night without
addition of Benzonase. The total protein concentration in the
supernatant (Figure 4A) was higher for almost all (NH4)2SO4
concentrations for precipitation from untreated lysate than for
dialyzed samples, as had been expected due to depletion of
molecules during dialysis. HBcAg concentrations in all three
experiments (Figure 4B) were comparable, except for the region
between 100 and 150 mM (NH4)2SO4, where supernatant HBcAg
concentrations during precipitation from non-dialyzed lysate
dropped significantly at 100 mM (NH4)2SO4, while the dialyzed
samples remained at comparably constant HBcAg concentrations
from 0 to 100 mM (NH4)2SO4. SDS PAGE analysis (Figure 4C)
showed similar results based on band intensities.
To validate that precipitation incubation time is sufficient
at larger scale, HBcAg concentration in the supernatant was
investigated in 10 min intervals at the previously determined
150 mM (NH4)2SO4. Precipitation of HBcAg was already
completed directly after addition of (NH4)2SO4, judging visually
based on SDS PAGE scans (Figure 5). It has to be noted that to
the first sampling time 2–3 min have to be added, accounting
for drawing of samples, transferring the samples into reaction
tubes, and centrifugation of the samples. Interestingly, during
titration of the untreated lysate with (NH4)2SO4, we observed
a rapid increase in turbidity when a concentration of 100 mM
(NH4)2SO4 was exceeded. Nevertheless, 150 mM (NH4)2SO4 and
a precipitation duration of 30 min were chosen to include a safety
margin, which was successful in all processes.
Centrifugation-Based Reference Process
After precipitation, solid-liquid separation aims at separating
the contaminant solutes and precipitation buffer from the
precipitated product. A wash step increases the efficiency
of contaminant removal. The Reference process was based
on centrifugal solid-liquid-separation for precipitate recovery,
wash, and re-dissolution. HBcAg concentration of re-dissolution
supernatant increased over the first 3 h and was 1.67, 1.80,
and 1.85 g/L, respectively (Figure 6A). Table 1 shows the
re-dissolution concentration and purity measures after 3 h,
where SEC purity was 76%, HT-CGE purity was 83%, and
A260/280 was 0.87. After precipitation, which was conducted
identically for all CFF processes and the Reference process,
the Reference process was completed in 4.5 h. Time-specific
productivities of all processes were calculated based on mg
HBcAg per hour relative to the Reference process productivity.
Therefore, the relative productivity of the Reference process
is 100%, as shown in Table 1. Assuming a similar area foot
print of the unit operations, a spatial component of the
productivity was neglected.
CFF-Based Wash and Re-dissolution
Processes – On-Line Monitoring and
Off-Line Analysis
While in the centrifugation-based Reference process, wash, re-
dissolution, and product recovery steps have to be performed
individually (Figure 2, Reference), the CFF set-up allows for
process step integration. Diafiltration with a wash buffer retains
the product while depleting solutes continuously. Diafiltration
into a re-dissolution buffer replaces the wash/precipitation buffer
and re-dissolves the product, which is then able to pass the 0.2µm
membrane. This additionally ensures that larger particles, such as
insoluble precipitate, are removed by retention. The developed
set-up facilitates fractionation of the permeate stream enabling
individual analysis of the fractions (Figure 3).
In the presented CFF processes, the wash step was stopped
when the initially saturated on-line UV absorbance in the
permeate fell below 4 mAU (for visualization of this process
see Supplementary Information S4). Product loss during the
wash step was determined by HT-CGE. HBcAg concentrations
in wash fractions were 0.02–0.03 g/L. The additional wash
step prior to precipitation of the Nuclease process resulted
in less than 0.1 mg HBcAg loss (analyzed by SEC). After
precipitation and wash, re-dissolution of the product was
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FIGURE 4 | Total protein and hepatitis B virus core antigen (HBcAg) concentration in the supernatant after precipitation depending on ammonium sulfate
[(NH4)2SO4] concentration. Total protein concentration by reducing high-throughput capillary gel electrophoresis (HT-CGE) is shown in (A), HBcAg concentration by
HT-CGE in (B). Experiments I-III represent precipitation (Prec.) from (I) lysate (-♢-), (II) lysate with added Benzonase dialyzed against digestion buffer overnight (-♢-),
and (III) lysate dialyzed against digestion buffer overnight without addition of Benzonase (-♢ ). Experiments I-III are also shown as reducing SDS PAGE scans (C),
where lanes 1–8 show (NH4)2SO4 concentrations. The HBcAg band is indicated by arrows.
initiated by switching DF buffer lines from wash buffer to re-
dissolution buffer. Figure 6B depicts on-line and off-line process
data over time for the re-dissolution step in the three CFF
process variants. Upon DF into re-dissolution buffer, on-line
permeate concentrations for all process variants increased to a
maximum after a lag phase of nearly 2 min and subsequently
decreased exponentially. The process was stopped as soon
as the on-line absorbance dropped below 4 mAU (on-line
concentration of 0.01 g/L). The final retentate was analyzed
for unrecovered product by HT-CGE. It showed a negligible
HBcAg mass of <0.5 mg for processes Basic and mmSEC, as
opposed to 22.4 mg in the Nuclease process. The maximum
on-line concentrations were 2.3, 2.2, and 0.4 g/L for processes
Basic, mmSEC, and Nuclease, respectively. The curve shapes
of the off-line HBcAg concentration are in good agreement
with the on-line data. In all three CFF processes, SEC purities
were the lowest in fraction F1 and constantly increased to
the purity maximum which coincided with the concentration
maximum. Maximum purities were 82, 99, and 94% for processes
Basic, mmSEC, and Nuclease, respectively. The SEC A260/A280
coefficient showed a nearly inverse progression compared to
SEC purity data.
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FIGURE 5 | SDS PAGE scan of (1) Invitrogen Mark 12 Unstained Standard, (2)
hepatitis B virus core antigen (HBcAg)-containing E. coli lysate, (3–6)
supernatant of precipitation experiments with 150 mM ammonium sulfate
directly, 10, 20, and 30 min after ammonium sulfate addition, and (7) pure
chimeric HBcAg sample. Molecular weights of the proteins contained in the
standard are shown on the left.
Comparison of Process Data
As seen from summarized process data (Table 1), processes
Basic and mmSEC showed higher HT-CGE purities and VLP
yields compared to the Reference process. SEC purity was
comparable between the Reference and the Basic process, while
it was highest for the mmSEC process. The mmSEC process also
showed lowest A260/A280 with 0.73. The relative productivities
of processes Basic and mmSEC were higher than the Reference
and the Nuclease process with >239%. While processes Basic and
mmSEC were superior with regard to aforementioned process
data, their concentrations were lower with 0.34–0.38 g/L as
compared to 1.85 g/L for the Reference process. To increase pool
concentrations, higher concentrated fractions can be selected for
pooling. Strategic pooling increased concentrations for processes
Basic and mmSEC to 1 g/L while maintaining purity and
productivity. However, the yield decreased to 57–68%. Overall,
the mmSEC process showed highest recovered mass, yield, SEC
purity, and lowest A260/A280, along with high productivity
and HT-CGE purity, both for strategic pooling and pooling
of all fractions.
The Nuclease process showed great product loss during re-
dissolution, as mentioned above. It exhibited the lowest yield
and relative productivity of 22 and 8%, respectively. Due to
low concentrations, purity is not comparable to the other
processes. For completeness, these values are plotted in Figure 6B
and shown in Table 1. Compared to the other processes,
the precipitation process following nuclease treatment started
with altered solution conditions regarding NaCl, MgCl2, EDTA,
and impurity concentrations. Five screening experiments were
designed to investigate the influence of solution conditions
during precipitation on re-dissolution efficiency. The recovery
of HBcAg in the re-dissolution experiments was 82 ± 1%,
indicating no significant difference in HBcAg recovery between
the investigated experimental conditions.
VLP Size Analysis
SEC, coupled to DAD, MALS, and QELS, detected three peaks
attributed to HBcAg (compare Supplementary Information
S3 for peak identification). A main peak was identified with
15.3–15.5 nm rms radius and 16.4–17.7 nm hydrodynamic
radius, corresponding to 79–84% of the HBcAg peak area
in the CFF processes. In the Reference process, it was 65%.
The two earlier-eluting peaks showed 24.4–25.2 nm and 30.4–
32.0 nm radius, respectively. The molecular weights were 3.8–
4.1 MDa, 7.5–7.8 MDa, and 12.2–12.7 MDa for the three
peaks in ascending order by radius. Figure 7 shows TEM
micrographs of the processes Basic, mmSEC, Nuclease, and the
Reference process. Graphical analysis resulted in average radii
of 13.4 ± 1.2, 14.6 ± 1.5, 13.6 ± 1.2, and 15.3 ± 1.8 nm,
respectively, not showing distinct species as observed in SEC.
While samples from processes mmSEC and Reference showed a
spatially equal distribution of VLPs, Basic and Nuclease samples
appeared clustered.
DISCUSSION
Interpretation of Analytical Methods
In this study, SEC and HT-CGE have been applied to
determine concentrations and to identify the quantified species.
It is therefore important to discuss the meaning of the
analytical data as determined for the presented processes.
HT-CGE has been employed as, compared to SDS PAGE, a
high-throughput compatible and quantitative size-dependent
concentration analytical technique. HT-CGE purity informs
about the relative HBcAg fraction of the total protein content,
i.e., HBcAg protein purity. SEC is applied to assess particle size
and molecular weight, HBcAg and contaminant concentrations,
and additionally provides spectral data of the sample.
The ratio of the absorbance at 260 nm to the absorbance at
280 nm (A260/A280) is characteristic for the ratio of nucleic
acid to protein concentration, whereby higher A260/A280 values
indicate a larger fraction of nucleic acids (Wilfinger et al., 1997).
SEC purity describes purity based on all species absorbing at
280 nm, such as proteins and nucleic acids.
The combination of these two purity measures together with
the A260/A280 are thus seen to be powerful to describe a sample.
Figure 8 illustrates the connection between these measures.
For example, samples with high HT-CGE purity but lower
SEC purity therefore probably also show increased A260/A280
values, indicating nucleic acid contamination. It is important to
note that SEC measurements are more accurate than HT-CGE
measurements for concentration determination. This being said,
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FIGURE 6 | Re-dissolution protein concentration (conc.) and purity. Each figure column represents a re-dissolution process variant: (A) Reference and (B) Basic,
mmSEC and Nuclease. In subfigure (A), the Reference process concentration and purity data is shown based on off-line analysis of the supernatant after
centrifugation. Top row: Off-line concentrations (♢) were derived from size-exclusion chromatography (SEC) peak areas of hepatitis B virus core antigen (HBcAg)
species (Supplementary Information S3). Bottom row: SEC purity (♢) is defined as percentage of HBcAg peak area at 280 nm with respect to the area of all SEC
peaks at 280 nm. A260/A280 (♢) is defined as quotient of the cumulated SEC peak areas at 260 and 280 nm, respectively. Dotted lines are added to guide the eye.
In subfigure (B), on-line monitoring of the permeate concentration and off-line analysis of the corresponding permeate fractions (F, indicated by vertical lines) during
CFF are shown. The metrics of subfigure (A) are shown in subfigure (B) using the same symbols. Additional to these metrics, protein concentrations (–) are shown.
Protein concentrations are based on absorbance at 280 nm assuming the chimeric HBcAg extinction coefficient.
TABLE 1 | Summary of re-dissolution process data for centrifugation (Reference) and cross-flow filtration (Basic, mmSEC, Nuclease) processes. Process data above the
thin horizontal border are calculated based on a pool of all fractions. Results below this border are based on a fraction pool that aimed for a product concentration of at
least 1 g/L and a maximum yield. This was not possible for the Nuclease process. Values are calculated using total hepatitis B virus core antigen concentrations except
A260/A280, which is based on all species in the size-exclusion chromatography (SEC) chromatogram (Supplementary Information Figure S3.1). Best results of each
table column are printed in bold.
Mass† (mg) Yield‡ (%) Conc.† (gL−1) SEC purity† (% Area) A260/A280† (-) HT-CGE purity (%) Relative productivity† (%)
Reference 30.73 72 1.85 76 0.87 83 100
BasicCFF,§ 36.26 82 0.38 73 1.02 96 264
mmSECCFF,§ 37.82 86 0.34 96 0.73 96 239
NucleaseCFF,§ 9.72 22 0.18 86 0.82 98 8
BasicCFF,¶ 25.19 57 1.01 78 0.96 95 248
mmSECCFF,|| 30.01 68 1.00 98 0.70 96 269
CFF, cross-flow filtration process, †assessed by SEC, ‡for definition see section “Materials and Methods” Eq. 1, §pool of all fractions, ¶pool of fractions F3–F7, ||pool of
fractions F3–F8. Process data for pools were calculated by accumulating fraction process data. A260/A280: absorbance ratio of the sample at 260 to 280 nm; Conc.,
concentration; HT-CGE, high-throughput capillary gel electrophoresis; SEC, size-exclusion chromatography.
SEC could only be applied to rather clean, non-turbid samples
(see also Supplementary Information S5.1). Therefore, SEC
rather was applied to assess concentrations during re-dissolution
while lysate and precipitation/wash samples were assessed
by HT-CGE. Yields were calculated based on lysate HBcAg
concentrations and re-dissolution sample concentrations and
are therefore based on both HT-CGE and SEC measurements.
Discussion on comparability of yields can be found in
Supplementary Information S5.2.
Off-line SEC and HT-CGE analysis indicated that mainly
HBcAg species pass through the membrane upon re-dissolution.
It was therefore reasonable to convert the on-line UV absorbance
into an on-line HBcAg concentration value, applying the HBcAg
extinction coefficient. The good agreement between on-line and
off-line concentration profiles underlines the usefulness of this
approach. However, the mmSEC process set-up included an
additional purification step between the UV flow cell and the
fraction collector, making off-line samples purer than the on-line
measured permeate stream.
The MALS detector coupled to the SEC system provides an
estimate of molecular weight. HBcAg capsids naturally occur
as 180-mer with icosahedral symmetry T = 3 and as 240-mer
with symmetry T = 4 (Wynne et al., 1999). As SEC is incapable
of separating different capsid symmetries, the molecular weight
measured is the average weight of T = 3 and T = 4 capsid species.
The theoretical molecular weight for a chimeric T = 4 capsid is
4.8 MDa and a T = 3 capsid is 3.6 MDa. The SEC-MALS-derived
molecular weights of the latest-eluting HBcAg peak were between
3.8 and 4.1 MDa, representing 18/82% and 43/57% mixture of
T = 3/T = 4 capsids, respectively. In vitro, HBcAg VLPs are
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FIGURE 7 | Transmission electron microscopy micrographs of re-dissolution peak samples of four processes: Basic, mmSEC, Nuclease, and the Reference
centrifugation process. The magnification was 27000-fold.
FIGURE 8 | Illustration of the interdependence of derived purity measures.
Virus-like particles (VLPs) with different degree of contamination by host cell
proteins (HCPs) and nucleic acids (NAs) are shown. Size-exclusion
chromatography (SEC) provides the A260/A280 (ordinate) and SEC purity
(diagonal axis). A high-throughput capillary gel electrophoresis (HT-CGE)
protein assay provides the HT-CGE purity (abscissa). The gray highlighted
area is characterized by identical SEC purity, while HT-CGE purity and/or
A260/A280 describe the composition of the contaminants. A pure hepatitis B
virus core antigen VLP sample is characterized by 100% SEC purity, 100%
HT-CGE purity and an A260/A280 of ∼0.7.
predominantly T = 4, but can shift toward higher percentage of
T = 3 symmetry capsids upon VLP modification (Zlotnick et al.,
1996; Böttcher et al., 1997; Rybka et al., 2019). As an orthogonal
method, TEM imaging confirmed the presence of approximately
30 nm sized nearly spherical particles. TEM image-based size
measurements did not result in significant differences between
the VLP sizes in samples of the different processes. Due to
graphical sizing inaccuracies, TEM was unable to resolve different
HBcAg species as observed with SEC. These three differently
sized HBcAg species, of which the smallest corresponds to the
typical size of an HBcAg VLP, were observed in all CFF processes
and the Reference process. Interestingly, the VLP fraction of
these three peaks was similar in all the CFF processes but higher
than in the reference process. It would be interesting to analyze
these species separately in the following process steps, such as
disassembly, which is, however, out of the scope of this study.
Precipitation of Chimeric HBcAg VLPs
Precipitation of complex mixtures involves interactions that are
only partly understood (Przybycien, 1998). This has also recently
been pointed out in a study on PEG-induced precipitation
of mAbs (Großhans et al., 2019). Although differences were
small in our study, variations of HBcAg concentrations were
observed especially at 100 mM (NH4)2SO4, where supernatant
concentrations after precipitation from untreated lysate were
lowest. This is in accordance with previously reported results
on mAb precipitation from complex mixtures in the study
mentioned above, where precipitation from a complex mixture
led to higher precipitation propensity of product molecules
(Großhans et al., 2019). This rapid decrease in HBcAg solubility
at 100 mM concurs with the observed rapid turbidity increase
at 100 mM (NH4)2SO4 at a larger scale during the CFF
and centrifugation processes. Experiments on precipitation
incubation time revealed that the investigated HBcAg VLPs
precipitate almost immediately, which is fast compared to
incubation times of 15 min – 4 h for different VLPs and
precipitants stated in literature (Schagen et al., 2000; Tsoka et al.,
2000; Koho et al., 2012).
Product Loss in the Nuclease Process
The Nuclease process showed significantly lower concentrations
of recovered HBcAg, making it difficult to compare this process
variant to the other processes. Due to its low relative productivity
and comparably complicated process route, it is not competitive
with the Reference process and the other CFF processes Basic
and mmSEC. The low yield observed in this process is mainly
due to incomplete re-dissolution, with 22.4 mg of HBcAg in the
final retentate. In order to reveal the effect of different solution
conditions during the precipitation step, this was investigated in
small-scale re-dissolution experiments. However, no significant
differences could be identified when investigating the influence
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of NaCl, EDTA, MgCl2, and contaminants with regard to this
problem. Further reasons could be the additional wash step
by DF on a membrane of different material or overnight
incubation at RT, resulting in irreversible precipitation. Apart
from low yields, its low relative productivity derives from the
16 h Benzonase incubation, yet only increases to 42% if an
incubation time of 1 h at optimized digestion conditions would be
considered. From a scientific standpoint, it would be interesting
to identify which factors contributed to the low re-dissolution
yields, whereas from a technical standpoint this process route
cannot be justified.
Benefits of Process Transfer to a CFF
Unit
The main advantage in implementing CFF for precipitation/re-
dissolution lies in the combination of product recovery by
membrane retention with the capability of exchanging the
product-containing buffer in a single process step. During CFF
wash steps, impurities smaller than 0.2 µm are expected to
be washed out with the permeate. Impurity depletion was
observed in all processes indicated by the decrease of on-
line UV absorbance. HBcAg VLPs are expected to be retained
by the membrane due to the size of their precipitate, as
was seen for mAb precipitate in previous studies (Kuczewski
et al., 2011; Hammerschmidt et al., 2016). Although HT-
CGE results point at minor product loss during wash, it is
important to note, that all proteins of 19.5–21.5 kDa were
assigned to HBcAg in our analysis due to sizing inaccuracies.
Therefore, product loss is expected to be lower than reported.
The wash process step was comparable for processes Basic
and mmSEC. Higher protein purities in the CFF processes
are probably due to a more efficient wash as compared to
the centrifugation-based Reference process, whereby interstitial
pellet liquid cannot be removed. However, in the Basic
process, SEC purity was slightly lower and A260/A280 higher
than in the Reference process. This indicates that the main
impurity in the Basic process are nucleic acids. This is in
accordance with previous unpublished results of CFF-based
processes from our group. It may be suggested that DNA
interacts with the VLPs in the kosmotropic environment
during precipitation and wash which hampers its depletion
during the wash step.
As opposed to re-dissolution of the compact pellet in the
Reference process, re-dissolution from a turbid solution in CFF-
based processes was expected to improve process performance.
This was for example observed by the increased yields of
processes Basic and mmSEC compared to the Reference process.
Product loss in the Reference process can be attributed to
unrecoverable interstitial pellet liquid and high precipitate
compaction (Hammerschmidt et al., 2016), which leads to
slower and incomplete re-dissolution. This is in agreement with
comparably slow re-dissolution in the Reference process. As
a result, CFF processes Basic and mmSEC showed strongly
enhanced relative productivities. Additionally, CFF process
durations are reduced by minimizing manual handling compared
to the Reference process. The mmSEC process showed superior
SEC purity compared to all other processes. As discussed above,
the main contaminant in the Basic process are nucleic acids.
These were efficiently depleted in the mmSEC process, leading
to excellent purity, while maintaining the increased yield of
the Basic compared to the Reference process, underpinning
the usefulness of the mmSEC column in the permeate
line (Figure 3).
In summary, process transfer to the CFF set-up led to
improved yields, accelerated re-dissolution kinetics, and process
intensification by integrating multiple process steps into one
unit operation. Compared to literature VLP processes showing
a 31–76% recovery (Zhao et al., 2015; Carvalho et al., 2019),
up to 95% protein purity (Wetzel et al., 2018), and a 78%
nucleic acid reduction (Carvalho et al., 2019), the process
data of the mmSEC process are comparable or superior while
applying only a single unit operation after lysate clarification.
The main drawback of the CFF-based processes were lower
product concentrations as compared to the Reference process.
The exponential permeate concentration decrease observed
for all re-dissolution processes, as expected for non-retained
species in DF (Kurnik et al., 1995), results in decreased
concentrations when aiming for a maximized process step
yield. Although the re-dissolution concentration profile cannot
be improved from a technical point of view, this effect can
be ameliorated by strategic pooling. This was exemplified
by creating 1 g/L pools, which resulted in improved purity
and 18–25% yield decrease. Alternatively, collection of all
fractions followed by a concentration process via UF could
maximize both yield and concentration. Another interesting
option would be loading the permeate onto an anion exchange
column or membrane as a polishing step to bind VLPs, deplete
(NH4)2SO4, and achieve further purification from other
contaminants while obtaining concentrated VLPs in the elution
step. While it seems reasonable to dissolve the precipitated
product by dilution to avoid DF-associated concentration
decrease, DF shows several advantages. Considering 0%
retention, 40% of (NH4)2SO4 is theoretically found in
fractions 1–2, which could be discarded due to low VLP
concentrations. On the contrary, all (NH4)2SO4 remains in
the product solution for re-dissolution by dilution as used
in several concepts for mAb capture processes (Kuczewski
et al., 2011; Hammerschmidt et al., 2016; Li et al., 2019).
This drawback may be circumvented by employing dead-end
filtration to drain precipitate before re-dissolution (Chen
et al., 2016; Liu et al., 2019; Lohmann and Strube, 2020).
This approach was not considered in this study to avoid
unknown effects of draining, precipitate compaction on
the membrane, and uncontrolled concentration increase on
product stability and yield. DF allows for highly efficient
(NH4)2SO4 removal in the retentate enabling maximum re-
dissolution and therefore yield. Conversely, comparable levels
of (NH4)2SO4 can only be reached by dilution to very large
volumes. Especially if a UF step is established after re-dissolution,
a simple DF step after concentration can remove residual
(NH4)2SO4 efficiently.
To the best of our knowledge, this is the first study to
present a fully integrated CFF system-based precipitation,
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wash and re-dissolution set-up for VLP capture and
purification that includes DF-based re-dissolution. The
presented approach showed exceptionally good performance
with regard to yield, purity, and productivity while being
based on a simple lab-scale set-up with basic commercial
devices. As a filtration-based process, it exhibits good
scalability and the possibility of disposable manufacturing
(van Reis and Zydney, 2007). For vaccines, especially
cancer vaccines, which are envisaged to be produced as
personalized medicine (Buonaguro et al., 2013; Rammensee
and Singh-Jasuja, 2013; Castiblanco and Anaya, 2015), this
highly efficient, easy-to-control, and scalable process could
enable distributed manufacturing of personalized protein
nanoparticle-based therapeutics.
Considerations for Method Transfer
From a technical point of view, CFF process control of the
presented method can be achieved by maintaining a constant
transmembrane pressure (TMP) or permeate flow rate. In case
of TMP-based control, low TMP values are required to obtain
the target permeate flow rate due to the large membrane pore
size of 0.2 µm. During wash and re-dissolution in processes Basic
and mmSEC, the TMP was in the range of 0.01 bar to 0.02 bar.
Therefore, a careful adjustment of the TMP is recommended
to avoid exceeding the maximum flow rate of the mmSEC
column. Nevertheless, a constant flow rate is advantageous for
fractionation and mmSEC separation.
The prerequisites for the successful application of this process
to the purification of other VLPs are the ability (I) to precipitate
the target product, (II) to retain the majority of impurities in
solution, (III) to re-dissolve the product, and (IV) to avoid
electrostatic or hydrophobic interaction between product and
impurities or matrices, such as the membrane material. These
prerequisites are probably fulfilled – to varying degrees – for most
non-enveloped VLPs.
Precipitation of the target product might require adaption
of the precipitant concentration or agent for different VLPs.
From unpublished results of our group, we learned that
the precipitation of other chimeric HBcAg VLPs required
ammonium sulfate concentrations of 0.1 M to 1 M. Their
large size compared to the typical contaminants facilitates
the precipitation of VLPs while retaining most impurities in
solution. The application of this process to smaller product
molecules (such as capsomers) could also be feasible, if a suitable
precipitation method is developed, which retains impurities in
solution. Product re-dissolution and hydrophobic or electrostatic
interactions are influenced by the solution conditions, which
might need to be optimized, presumably with a focus on the
optimum solution pH.
Compared to the here investigated non-enveloped VLPs,
enveloped VLPs might pose a challenge due to their lower
stability (Dai et al., 2018). VLPs derived from other hosts
such as yeast or plants require changes in the lysis procedure
and bring along a different impurity profile than E. coli.
This said, the separation in the presented process is largely
based on the size difference between product and impurities,
which should be comparable for other hosts. Extracellularly
produced VLPs could benefit from the higher purity of
the starting material and therefore potentially result in yet
higher purities using this process. Conclusively, the transfer
of this method to the purification of other VLPs probably
requires few adaptations, mainly regarding the development
of optimal solution conditions for VLP precipitation and re-
dissolution in small scale.
CONCLUSION AND OUTLOOK
In this study, we have developed a set-up for integrated capture
and purification of VLPs within a CFF unit. Clarified lysate
was precipitated, washed, and re-dissolved. Three CFF process
variants were investigated and characterized for yield, purity,
and relative productivity and were compared to a centrifugation-
based Reference process. Process transfer of the Reference process
to the CFF unit led to increased purities, probably attributed
to a more efficient wash step. The mmSEC process, integrating
an additional purification step by an mmSEC column in the
permeate line, was superior to all tested variants and the Reference
process resulting in the highest purity and productivity. As
one single unit operation, it compares favorably to entire DSP
processes found in the literature and shows great potential for
disposable and scalable manufacturing. Another key advantage
of CFF processes is the possibility to fractionate the VLP-
containing permeate, allowing for efficient pooling with regard
to the desired target process data and product analytical profile.
In the future, this mainly size-based DSP step could be applied
to other VLPs or similarly sized therapeutics with only minor
adaptations, laying the foundation for a platform process for
protein nanoparticles.
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